2013-11-15T15:24:35-06:00 2012-12-31 BDO USA LLP 8405 GREENSBORO DRIVE 7TH FLOOR MCLEAN VA 22102 990 2012-01-01 522044704 AERAS % GERARD FLEURY AERA 3015472900 1405 RESEARCH BLVD Suite 300 ROCKVILLE MD 20850 GERARD FLEURY 3015472946 2013-11-15 true Jeffrey J Schragg 7038930600 2013-11-14 2012 2016-03-07 17:11:31Z THOMAS EVANS 1405 RESEARCH BLVD ROCKVILLE MD 20850 48699346 false X WWW.AERAS.ORG X 1997 DC A NON-PROFIT PRODUCT DEVELOPMENT ORG DEDICATED TO THE DEVELOPMENT OF EFFECTIVE TUBERCULOSIS (TB) VACCINES AND BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE AND SUSTAINABLE MANNER. 10 9 170 9 209588 -870184 47923628 47025200 1335024 893761 119590 175709 162926 -36126 49541168 48058544 1038650 2132586 0 0 17109403 19671886 0 0 0 28595246 27892213 46743299 49696685 2797869 -1638141 48430676 43841249 10280132 7520117 38150544 36321132 X AERAS IS A NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATION DEDICATED TO THE DEVELOPMENT OF EFFECTIVE TUBERCULOSIS (TB) VACCINES AND BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE AND SUSTAINABLE MANNER. AERAS UTILIZES ITS BROAD CAPABILITIES AND TECHNOLOGIES IN COLLABORATION WITH NUMEROUS PARTNERS AND STAKEHOLDERS TO SUPPORT THE DEVELOPMENT OF VACCINES AND OTHER BIOPHARMACEUTICALS TO ADDRESS TB AND OTHER SIGNIFICANT PUBLIC HEALTH NEEDS OF UNDERSERVED POPULATIONS. IN THE PURSUIT OF OUR MISSION, WE ARE GUIDED BY OUR CORE VALUES. THESE CORE VALUES EXPRESS OUR ASPIRATIONS AND THE BEHAVIORS WE WANT TO EXHIBIT AND MODEL. THEY SHAPE THE CULTURE AND CHARACTER OF AERAS AND INFORM ALL OF OUR DECISIONS AND ACTIONS. false false 7137103 Discovery/Preclinical - Aeras develops and assesses a range of vaccine platforms and variations, and explores novel approaches to enhance the effectiveness of new TB vaccines in effective prime-boost regimens. Aeras evaluates TB vaccine candidates to determine whether they have the characteristics needed to move forward to the next phase of development. Key elements include evaluation of safety, immunogenicity and the protection the candidates provide in animal models. An independent panel of vaccine experts evaluates all relevant preclinical data before a candidate is approved for entry into Phase I trials. Aeras also supports the assessment of novel assays that could be implemented at the clinical stage of development to drastically reduce the time and cost of developing new vaccines against tuberculosis. 17274996 Clinical - Aeras and its research partners have transformed the TB vaccine clinical landscape. Six vaccine candidates are undergoing testing in clinical trials in Kenya, Senegal, South Africa, the United Kingdom, and the United States with support from Aeras for protocol development, safety monitoring, regulatory and immunology. We also design and conduct epidemiology studies to estimate TB prevalence and/or incidence under real-world trial conditions to inform ongoing studies and to assess the feasibility of conducting large-scale clinical trials in TB at additional research sites in TB endemic countries, including China. 13265328 891588 Tech Operations - Vaccine manufacturing facility located at Aeras headquarters designed to manufacture internally developed vaccine candidates based on a range of technology platforms capabilities in bacterial, viral and protein vaccines. Aeras has cGMP-compliant, end-to-end equipment and operating capabilities that meet both US FDA and European EMEA standards. Process development and manufacturing capabilities support translation from research to clinical development, including manufacturing of clinical trial materials for Aeras-sponsored trials. THE Facility is also used in collaboration with external vaccine partners and contract product development services clients. 6112205 2173 43789632 true true false false false false false false false false true true false false true true false true false true true true false false false false false true false true false false false false false false false false false false false false false true true true false false true X 68 0 170 true true true true SF HK false false false false false false false false X 10 9 false false false false false false false true true false false true true true true true true true true false MD X X GERARD FLEURY 3015472964 1405 RESEARCH BLVD STE 300 ROCKVILLE MD 20850 X R GORDON DOUGLAS JR 1.0 X 0 0 0 MICHEL GRECO MS MBA 1.0 X 0 0 0 PETER BARTON HUTT LLM 1.0 X 0 0 0 HOOSEN COOVADIA MD 1.0 X 0 0 0 REGINA RABINOVICH MD MPH 1.0 X 0 0 0 JAMES CONNOLLY 40.0 X X 638835 0 18746 WAYNE PISANO 1.0 X 0 0 0 LOTA ZOTH 1.0 X 0 0 0 GERD ZETTLMEISSEL 1.0 X 0 0 0 BARRY BLOOM 1.0 X 1000 0 0 ANN M GINSBERG MD PHD 40.0 X 301972 0 21087 ERIC TSAO 40.0 X 249223 0 31285 JOHN BRUCE MCCLAIN 40.0 X 279229 0 24541 THOMAS EVANS 40.0 X 473130 0 32822 GERARD FLEURY 40.0 X 281034 0 29295 KEVIN SLY 40.0 X 264426 0 29295 RITA KHANNA 40.0 X 212392 0 14563 WENDY PENRY 40.0 X 155108 0 22177 KARI STOEVER 40.0 X 190540 0 13724 LEWELLYS BARKER 40.0 X 235463 0 19213 ROBERT WALKER 40.0 X 290719 0 16476 SADRITIN ISHMUKHAMEDOV 40.0 X 185626 0 15465 REGINALD KIDD 40.0 X 162399 0 26790 MICHAEL BRENNAN 40.0 X 213595 0 18199 MARGARET GOETZ 40.0 X 213944 0 13181 BARBARA SHEPHERD 40.0 X 183166 0 22515 DWAYNE WILSON 40.0 X 175441 0 15491 LINDA DUNTON 40.0 X 180938 0 27110 4888180 0 411975 61 false true false UNIVERSITY OF CAPE TOWN RONDEBOSCH CAPETOWN 0 SF 7700 VACCINE DEV/RESEARCH 3499149 OREGON HEALTH SCIENCE UNIVERSITY VACCINE DEV/RESEARCH 1430694 KENYA MEDICAL RESEARCH MBAGATHI RD NAIROBI 0 KE 00200 VACCINE DEV/RESEARCH 686392 UNIVERSITY OF PITTSBURGH VACCINE DEV/RESEARCH 705490 THE BOSTON CONSULTING GROUP PROFESSIONAL SERVICE 597801 38 6074293 40950907 47025200 VACCINE MANUFACTURING 541900 891588 682000 209588 0 MISCELLANEOUS 900099 2173 2173 0 0 893761 175709 0 0 175709 0 0 604676 640802 -36126 0 -36126 -36126 0 0 0 0 0 48058544 684173 209588 139583 586125 586125 0 0 1546461 1546461 0 0 4236575 2863426 1373149 0 0 0 0 0 12318715 11197024 1121691 0 613578 562941 50637 0 1340384 1188451 151933 0 1162634 1020348 142286 0 0 0 0 0 372351 9736 362615 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2490602 1199846 1290756 0 0 0 0 0 624818 376660 248158 0 0 0 0 0 0 0 0 0 4806977 4538676 268301 0 762774 593771 169003 0 0 0 0 0 622240 493163 129077 0 0 0 0 0 0 0 0 0 4221613 3992044 229569 0 215053 92315 122738 0 CONTRACT SERVICES 9568929 9532795 36134 0 COLLABORATION AGREEMENTS 608599 608599 0 0 LAB SUPPLIES AND MATERIALS 1440714 1440714 0 0 ANIMAL STUDIES 1617503 1617503 0 0 540040 329034 211006 49696685 43789632 5907053 0 300 300 31797528 3458884 325449 1291735 409877 47548 0 0 0 0 0 0 0 0 241041 769768 36278215 24506751 15452326 11771464 0 0 0 26168019 0 0 0 0 204155 333531 48430676 43841249 6171078 5411737 0 174145 2264872 225190 0 0 0 0 0 0 0 0 0 0 1844182 1709045 10280132 7520117 X 14993955 10231637 23156589 26089495 0 0 38150544 36321132 48430676 43841249 X -1638141 31097 -222368 X false true X true true true X JOHNS HOPKINS HOSPITAL BALTIMORE MD OREGON SCIENCE AND HEALTH UNIVERSITY PORTLAND OR ST LOUIS UNIVERSITY ST LOUIS MO RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 0 0 18289672 10101588 8188084 0 15049031 11824913 3224118 0 2939512 2580250 359262 11771464 0 0 DEFERRED RENT 1668354 DEFERRED 457 PLAN 40691 1709045 47902042 31097 -223725 -192628 48094670 -36126 -36126 48058544 49743990 47305 47305 49696685 49696685 OTHER REVENUE ON BOOKS BUT NOT ON RETURN FORM 990, SCHEDULE D, PART XI, LINE 2D CONSOLIDATED FOREIGN CURRENCY LOSS (49,889) INCOME OF AFFILIATE 1,339,677 ELIMINATIONS (1,339,368) REFUNDS OF CONTRIBUTIONS FROM PRIOR YEARS (174,145) ----------- TOTAL (223,725) OTHER EXPENSES ON BOOKS BUT NOT ON RETURN FORM 990, SCHEDULE D, PART XII, LINE 2D EXPENSES OF AFFILIATE 1,350,547 ELIMINATIONS (1,339,368) RENTAL INCOME (604,676) RENTAL EXPENSE 640,802 ----------- TOTAL 47,305 FIN 48 FOOTNOTE FORM 990, SCHEDULE D, PART X, LINE 2 In accordance with authoritative guidance issued by the FASB, Aeras would recognize a tax liability when, despite management's belief that tax return positions are supportable, management believes that certain positions may not be fully sustained upon review by tax authorities. Liabilities for uncertain tax positions would be measured based upon the largest liability that is greater than 50% likely to be incurred on any settlement with taxing authorities. To the extent that the final tax outcome of these matters would differ from the liabilities recorded, such differences would be included in income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments also would be included in income tax expense. Management has evaluated Aeras' tax positions and has concluded that Aeras has taken no material uncertain tax positions that require adjustment to the consolidated financial statements to comply with the provisions of this guidance. Aeras is currently under no income tax examinations in any Federal, or state or local jurisdictions. Aeras is generally no longer subject to income tax examinations by the U.S. federal, state or local tax authorities for years ended December 31, 2008 and prior. OTHER REVENUE ON RETURN BUT NOT ON BOOKS FORM 990, SCHEDULE D, PART XI, LINE 4B RENTAL INCOME 604,676 RENTAL EXPENSE (640,802) ----------- TOTAL (36,126) true Central America and the Caribbean 0 0 Program Services CLINICAL 3090 East Asia and the Pacific 1 0 Program Services CLIN/COLLABOR 240453 Europe (Including Iceland and Greenland) 0 0 Program Services CLIN/TECH OPS/DISC 3852510 Middle East and North Africa 0 0 Program Services GLOBAL COLLABOR 781 North America 0 0 Program Services DISC/TECH OPS/COLLAB 75362 South Asia 0 0 Program Services CLIN/COLLABOR 39322 Sub-Saharan Africa 1 14 Program Services CLINICAL 6642685 2 14 2 14 10854203 10854203 Sub-Saharan Africa SEE PART V 60193 EFT cash Europe (Including Iceland and Greenland) SEE PART V 88912 EFT CASH Sub-Saharan Africa SEE PART V 1397356 EFT CASH 3 true false true false false false MONITORING THE USE OF GRANTS FORM 990, SCHEDULE F, PART I, LINE 2 Aeras receives a request for support. Senior management reviews the request through the due diligence criteria approved by the Board and implemented by management. For example, the grantee must be a charity either under US law or under local law. Aeras may request governance documents from the organization, IRS determination letter (or local equivalent) indicating it is a charity, lists of executive staff and board members, and financial statements of the requestor. Upon management approval, funds are sent to the requesting organization. Copies of the request and payment are maintained at Aeras. PURPOSE OF GRANT FORM 990, SCHEDULE F, PART II, COLUMN (D) THE PURPOSE OF THE GRANT IS TO SUPPORT THE MISSION OF THE ORGANIZATION, TO DEVELOP, TEST, CHARACTERIZE, LICENSE, MANUFACTURE AND DISTRIBUTE NEW TB VACCINE. true ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHEVA UNI 1300 MORRIS PARK AVENUE NEW YORK NY 10461 32065 SEE PART V SAINT LOUIS UNIVERSITY 221 N GRAND BLVD ST LOUIS MO 63103 22365 SEE PART V OREGON HEALTH AND SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND OR 97239 531695 SEE PART V MONITORING THE USE OF GRANTS FORM 990, SCHEDULE I, PART I, LINE 2 The grants provided are sub-Awards related to federal grants. Aeras requires copies of A-133 audit reports, periodic financial reports, as well as periodic programatic progress reports. X true false X X X X X X true false false false false false false false false ANN M GINSBERG MD PHD 299472 0 2500 0 0 0 15000 0 6087 0 323059 0 0 0 LEWELLYS BARKER 231463 0 4000 0 0 0 13570 0 5643 0 254676 0 0 0 ERIC TSAO 246473 0 2750 0 0 0 14757 0 16528 0 280508 0 0 0 JOHN BRUCE MCCLAIN 161229 0 6000 0 112000 0 6923 0 17618 0 303770 0 0 0 MICHAEL BRENNAN 209595 0 4000 0 0 0 12515 0 5684 0 231794 0 0 0 JAMES CONNOLLY 494835 0 144000 0 0 0 15000 0 3746 0 657581 0 0 0 THOMAS EVANS 395214 0 77916 0 0 0 15000 0 17822 0 505952 0 0 0 ROBERT WALKER 285719 0 5000 0 0 0 12692 0 3784 0 307195 0 0 0 MARGARET GOETZ 208944 0 5000 0 0 0 4139 0 9042 0 227125 0 0 0 BARBARA SHEPHERD 177698 0 5468 0 0 0 10552 0 11963 0 205681 0 0 0 SADRITIN ISHMUKHAMEDOV 180218 0 5408 0 0 0 0 0 15465 0 201091 0 0 0 DWAYNE WILSON 172141 0 3300 0 0 0 10267 0 5224 0 190932 0 0 0 GERARD FLEURY 275034 0 6000 0 0 0 12692 0 16603 0 310329 0 0 0 KEVIN SLY 257426 0 7000 0 0 0 12692 0 16603 0 293721 0 0 0 RITA KHANNA 209392 0 3000 0 0 0 12254 0 2309 0 226955 0 0 0 LINDA DUNTON 175370 0 5568 0 0 0 10829 0 16281 0 208048 0 0 0 WENDY PENRY 155108 0 0 0 0 0 7037 0 15140 0 177285 0 0 0 KARI STOEVER 190540 0 0 0 0 0 7754 0 5970 0 204264 0 0 0 REGINALD KIDD 156899 5500 0 0 0 9524 0 17266 0 189189 0 0 0 SEVERANCE PAYMENT FORM 990, SCHEDULE J, LINE 4A DURING THE TAX YEAR MR. John McClain RECEIVED A SEVERANCE PAYMENT IN THE AMOUNT OF $112,000. FORM 990 REVIEW PROCESS FORM 990, PART VI, LINE 11B A draft version of the Form 990 is shared with the Board of Directors of Aeras and once approved it is filed with the IRS. CONFLICT OF INTEREST POLICY FORM 990, PART VI, LINE 12c Aeras' policy is written to protect Aeras' interest when it is contemplating entering into a transaction or arrangement that might benefit the private interest of directors, committee members, officers, employees and retained consultants of Aeras. In connection with any actual or possible conflicts of interest, an interested person must disclose the existence of his or her interest and all material facts to the directors and members of the committee with board-delegated powers considering the proposed transaction or arrangement. After disclosure of all material facts and discussion with the person, the person shall leave the board or committee meeting while their determination of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. DETERMINING COMPENSATION FORM 990, PART VI, LINE 15 Aeras has a Compensation Committee which determines the CEO compensation level based on his responsibilities, size of the organization, funding levels and organization objectives. Compensation is based on comparability data, is approved by independent Board members, and the process is documented in the Board minutes. Compensation for other officers is determined by the CEO, based on the officer's responsibilities, funding levels and organization objectives. compensation is based on comparability data and is shared with independent board members. AVAILABILITY OF OTHER DOCUMENTS FORM 990, PART VI, LINE 19 Governing documents, including Articles of Incorporation, Bylaws, Board minutes, Conflict of Interest policy and financial statements are available upon request. OTHER PROGRAM SERVICES FORM 990, PART III, LINE 4D Aeras also works to build relationships that support its goal to develop TB vaccines through collaboration at the global and regional levels with multi-lateral organizations such as the European Union, the European Investment Bank, and the World Health Organization, among other TB researchers and vaccine developers, as well as with donors, advocates and policymakers who can help raise awareness and support for this work. Aeras' Scientific and External Affairs departments are critical to advancing these strategic partnerships to ensure global support. OTHER CHANGES IN NET ASSETS OR FUND BALANCES FORM 990, PART XI, LINE 9 US ENTITY FOREIGN CURRENCY LOSS: $(48,223) REFUNDS OF CONTRIBUTIONS FROM PRIOR YEARS $ (174,145) TOTAL: $ (222,368) AERAS SOUTH AFRICA BLACKRIVER PARK 1ST FLR CAPE TOWN OBSERVATORY SF 7925 CLINICAL TR SF N/A N/A NA true AERAS HONG KONG false true false false false false false false false false false false false false false false false false AERAS GLOBAL TB VACCINE FOUNDATION NPC B 1397356